Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
Massachusetts General Hospital
mi
from
Boston, MA
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
University of Pittsburgh School of Medicine
mi
from
Pittsburgh, PA
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
University of Pittsburgh School of Medicine
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
MT2004-30: Tomotherapy for Solid Tumors
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
MT2004-30: Tomotherapy for Solid Tumors
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood
Status: Enrolling
Updated:  12/6/2017
Children's Oncology Group
mi
from
Philadelphia, PA
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood
Status: Enrolling
Updated: 12/6/2017
Children's Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/8/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/8/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
St. Anthony Central Hospital
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
St. Anthony Central Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Porter Adventist Hospital
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
St. Joseph Hospital
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Swedish Medical Center
mi
from
Englewood, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Eastern Connecticut Hematology and Oncology Associates
mi
from
Norwich, CT
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Eastern Connecticut Hematology and Oncology Associates
mi
from
Norwich, CT
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Illinois CancerCare-Bloomington
mi
from
Bloomington, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Illinois CancerCare-Bloomington
mi
from
Bloomington, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
St. Joseph Medical Center
mi
from
Bloomington, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
St. Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Graham Hospital
mi
from
Canton, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Illinois CancerCare - Canton
mi
from
Canton, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Illinois CancerCare - Canton
mi
from
Canton, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Memorial Hospital
mi
from
Carthage, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
University of Illinois Cancer Center
mi
from
Chicago, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
University of Illinois Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Eureka Community Hospital
mi
from
Eureka, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Evanston Hospital
mi
from
Evanston, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Galesburg Clinic, PC
mi
from
Galesburg, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Illinois CancerCare - Havana
mi
from
Havana, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Illinois CancerCare - Havana
mi
from
Havana, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Illinois CancerCare - Kewanee Clinic
mi
from
Kewanee, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Illinois CancerCare - Kewanee Clinic
mi
from
Kewanee, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
La Grange Memorial Hospital
mi
from
La Grange, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
La Grange Memorial Hospital
mi
from
La Grange, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
McDonough District Hospital
mi
from
Macomb, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials